Chief Scientific Adviser Criticized For Large Investments In Vaccine Developer

Sir Patrick Vallance, the Chief Scientific Adviser to the Government of the United Kingdom, has been accused of having a conflict of interest, after a recent report revealed that he has a £600,000 stake in GlaxoSmithKline (GSK), the pharmaceutical company that is working to develop a COVID vaccine for the UK government.

Vallance holds 43,111 shares in the company, but what is perhaps more alarming is how he got the shares in the first place. Before getting his job with the UK government, Vallance was the president of GlaxoSmithKline, which illustrates the revolving door that exists between government agencies and the multinational corporations that they claim to be regulating. When Vallance was appointed to the government, he sold £5 million worth of the company’s shares, but still retained a sizeable stake in the company.

Naturalblaze Chief Scientific Adviser Criticized For Large Investments In Vaccine Developer

2 thoughts on “Chief Scientific Adviser Criticized For Large Investments In Vaccine Developer

  1. I have seen it suggested that herd immunity for Covid is low, about 20 percent. If true Lockdown was unnecessary, there is no urgency for a vaccine and certainly no need to vaccinate the entire population.

    Like

Comments are closed.